Valuation: Glaukos Corporation

Market Cap 10.05B 8.73B 8.14B 7.48B 14.14B 956B 14.3B 95.96B 37.51B 478B 37.75B 36.93B 1,584B P/E 2026 *
-211x
P/E 2027 * 581x
Enterprise Value 9.88B 8.58B 8B 7.35B 13.9B 940B 14.05B 94.29B 36.86B 470B 37.1B 36.29B 1,556B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 11.6x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-0.20%
1 week+12.69%
Current month+2.29%
1 month+14.96%
3 months+25.53%
6 months+48.71%
Current year+51.03%
1 week 165.37
Extreme 165.37
184
1 month 143.11
Extreme 143.11
184
Current year 93.96
Extreme 93.96
184
1 year 73.16
Extreme 73.16
184
3 years 59.22
Extreme 59.22
184
5 years 33.33
Extreme 33.33
184
10 years 23.08
Extreme 23.075
184
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
09/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
06/07/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
Change 5-day change 1-year change 3-year change Capi.($)
-0.20%+12.69%+94.89%+129.15% 10.07B
-1.54%-3.07%-11.93%+18.42% 131B
-6.27%-6.50%-2.77%-0.40% 13.52B
-0.94%-0.71%-42.73%-68.98% 4.73B
+1.17%-0.67%-12.11%+36.19% 2.58B
-1.78%+4.54%+15.88%-47.90% 1.81B
-1.51%+4.23%-28.97%-31.15% 1.71B
-0.47%+3.08%-17.61%-18.11% 1.68B
+22.83%+23.42%-50.64%-76.86% 1.5B
Average +1.25%+1.05%-6.22%-6.63% 18.72B
Weighted average by Cap. -1.55%-2.09%-5.95%+18.92%

Financials

2026 *2027 *
Net sales 691M 600M 559M 514M 972M 65.7B 982M 6.59B 2.58B 32.84B 2.59B 2.54B 109B 842M 731M 682M 626M 1.18B 80.08B 1.2B 8.04B 3.14B 40.03B 3.16B 3.09B 133B
Net income -51.88M -45.05M -42M -38.59M -72.98M -4.94B -73.78M -495M -194M -2.47B -195M -191M -8.17B 18.93M 16.43M 15.32M 14.08M 26.62M 1.8B 26.91M 181M 70.62M 900M 71.07M 69.52M 2.98B
Net Debt -175M -152M -142M -130M -246M -16.64B -249M -1.67B -653M -8.32B -657M -642M -27.55B -273M -237M -221M -203M -384M -25.95B -388M -2.6B -1.02B -12.97B -1.02B -1B -42.99B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
04/08/26 US$170.53 -0.20% 799,689
03/08/26 US$170.87 +2.49% 1,108,936
31/07/26 US$166.72 -1.07% 1,032,220
30/07/26 US$168.52 +4.24% 2,559,596
29/07/26 US$161.66 +6.83% 3,137,806
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
170.53USD
Average target price
193.62USD
Spread / Average Target
+13.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock